BioCentury
ARTICLE | Company News

FDA approves Taiho's Lonsurf for mCRC

September 23, 2015 1:29 AM UTC

FDA approved Lonsurf trifluridine/tipiracil ( TAS-102) from Taiho Oncology Inc. to treat refractory metastatic colorectal cancer in patients previously treated with chemotherapy, an anti-VEGF biological therapy, and if Ras wild-type, an anti- EGFR therapy. Lonsurf, which has Fast Track designation from FDA, was approved ahead of its Dec. 19 PDUFA date.

Taiho Oncology plans to make the drug available in the U.S. this month, at which time it will announce the price. ...